Beigene Ltd (BGNE) CEO John Oyler Sold $7.3 million of Shares

GuruFocus.com
0

- By insider

CEO of Beigene Ltd (BGNE) John Oyler sold 85,906 shares of BGNE on 11/29/2017 at an average price of $84.66 a share. The total sale was $7.3 million.

BeiGene Ltd is a clinical-stage biopharmaceutical company engaged in the discovery & development of molecularly targeted & immuno-oncology drugs for the treatment of cancer. Its product includes BGB-3111, BGB-283 and BGB-290 and one immuno-oncology agent. BeiGene Ltd has a market cap of $3.77 billion; its shares were traded at around $82.99 with and P/S ratio of 17.41.


CEO Recent Trades:

  • CEO, 10% Owner John Oyler sold 85,906 shares of BGNE stock on 11/29/2017 at the average price of $84.66. The price of the stock has decreased by 1.97% since.

  • CEO, 10% Owner John Oyler sold 150,957 shares of BGNE stock on 11/15/2017 at the average price of $80.5. The price of the stock has increased by 3.09% since.

Directors and Officers Recent Trades:

  • CMO, Hematology Jane Huang sold 1,600 shares of BGNE stock on 11/20/2017 at the average price of $86.25. The price of the stock has decreased by 3.78% since.

  • CMO, Immuno-oncology Amy C. Peterson sold 3,601 shares of BGNE stock on 11/13/2017 at the average price of $82.96. The price of the stock has increased by 0.04% since.

For the complete insider trading history of BGNE, click here

.This article first appeared on GuruFocus.


Advertisement

Recommended Stories